Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Cartesian Therapeutics (RNAC) Other Non Operating Income (2016 - 2026)

Cartesian Therapeutics (RNAC) has disclosed Other Non Operating Income for 12 consecutive years, with -$3000.0 as the latest value for Q1 2026.

  • For Q1 2026, Other Non Operating Income changed N/A year-over-year to -$3000.0; the TTM value through Mar 2026 reached -$2.0 million, down 2154.08%, while the annual FY2025 figure was -$2.0 million, 431.68% down from the prior year.
  • Other Non Operating Income hit -$3000.0 in Q1 2026 for Cartesian Therapeutics, up from -$2.0 million in the prior quarter.
  • Across five years, Other Non Operating Income topped out at $652000.0 in Q4 2023 and bottomed at -$2.0 million in Q4 2025.
  • Average Other Non Operating Income over 5 years is -$43428.6, with a median of $21000.0 recorded in 2023.
  • Year-over-year, Other Non Operating Income soared 25200.0% in 2023 and then tumbled 351.58% in 2025.
  • Cartesian Therapeutics' Other Non Operating Income stood at -$177000.0 in 2022, then skyrocketed by 468.36% to $652000.0 in 2023, then crashed by 168.1% to -$444000.0 in 2024, then crashed by 351.58% to -$2.0 million in 2025, then skyrocketed by 99.85% to -$3000.0 in 2026.
  • According to Business Quant data, Other Non Operating Income over the past three periods came in at -$3000.0, -$2.0 million, and -$5000.0 for Q1 2026, Q4 2025, and Q2 2025 respectively.